Valuation: AbbVie

Market Cap 448B 392B 363B 334B 629B 43,169B 639B 4,337B 1,700B 21,122B 1,681B 1,644B 72,772B P/E 2026 *
33x
P/E 2027 * 23.4x
Enterprise Value 504B 442B 408B 376B 709B 48,607B 720B 4,883B 1,914B 23,783B 1,893B 1,851B 81,939B EV / Sales 2026 *
7.5x
EV / Sales 2027 * 6.81x
Free-Float
95.71%
Yield 2026 *
2.71%
Yield 2027 * 2.86%
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/03/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 69 01/01/2013
Change 5-day change 1-year change 3-year change Capi.($)
-8.07%-3.48% - - 450B
-2.73%-2.96%+48.62%+147.27% 1,051B
-1.67%-3.47%+52.00%+47.77% 609B
-0.75%-1.46%+28.32%+22.33% 330B
-1.52%-0.95%+33.38%+38.39% 284B
-1.70%-3.54%+20.26%+17.88% 263B
-0.58%+1.78%-20.89%-38.37% 223B
-0.58%+1.03%+23.55%+56.14% 198B
-0.80%+1.38%+23.09%+66.64% 167B
-1.20%+1.10%+1.14%-32.69% 143B
Average -1.56%-0.28%+23.28%+36.15% 363.13B
Weighted average by Cap. -1.83%-1.43%+33.95%+66.06%

Financials

2026 *2027 *
Net sales 67.25B 58.95B 54.49B 50.11B 94.55B 6,485B 96.07B 652B 255B 3,173B 253B 247B 10,932B 72.81B 63.82B 58.99B 54.25B 102B 7,021B 104B 705B 277B 3,435B 273B 267B 11,836B
Net income 14.44B 12.65B 11.7B 10.76B 20.3B 1,392B 20.62B 140B 54.82B 681B 54.21B 53.03B 2,347B 18.98B 16.64B 15.38B 14.15B 26.69B 1,831B 27.12B 184B 72.09B 896B 71.28B 69.73B 3,086B
Net Debt 56.39B 49.42B 45.68B 42.02B 79.28B 5,438B 80.55B 546B 214B 2,661B 212B 207B 9,166B 47.87B 41.96B 38.79B 35.67B 67.31B 4,617B 68.39B 464B 182B 2,259B 180B 176B 7,782B
Logo AbbVie
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
-
Trader
Investor
Global
Quality
-
ESG MSCI
AA